Continuing Education
for Urology & GU Oncology Clinicians
Washington, DC (UroToday.com) Dr. Seth Lerner presented the second State of the Art Lecture at the Society of Urologic Oncology Annual Meeting in Washington, D.C. discussing the landscape of advanced bladder cancer following the working of The Cancer Genome Atlas (TCGA) project. The TCGA work has made significant contributions to our understanding of the genomic and molecular underpinnings of urothelial carcinoma.1,2
Non-Accredited
Washington, DC (UroToday.com) On the final day of the Society of Urologic Oncology Meeting (SUO 2019), the six best abstracts submitted were selected for presentation. One of these highlighted studies from Memorial Sloan Kettering Cancer Center (MSKCC) evaluated the differential response of high grade non-muscle invasive bladder cancer to Bacillus Calmette-Guerin (BCG) on the basis of FGFR3 alterations. Dr. Timothy Clinton, a urologic oncology fellow at MSKCC, presented the group’s findings.
Non-Accredited
Washington, DC (UroToday.com) During the bladder cancer session at the Society of Urologic Oncology Meeting on Thursday, December 5th, Dr. Colin Dinney presented the results of a phase III clinical trial for Adstiladrin® (rAd-INFa/syn3) in BCG unresponsive non-muscle invasive bladder cancer.
Non-Accredited